Extent of Cross-Resistance between Agents Used To Treat Human Immunodeficiency Virus Type 1 Infection in Clinically Derived Isolates
Open Access
- 1 March 2002
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (3), 909-912
- https://doi.org/10.1128/aac.46.3.909-912.2002
Abstract
The phenomenon of cross-resistance to antiretroviral agents used to treat human immunodeficiency virus type 1 infection is well known but so far has been only qualitatively described. Here, we quantitate the degree of cross-resistance among all commonly prescribed antiretroviral agents in almost 5,000 clinically derived recombinant isolates collected in the United States since January 2000.Keywords
This publication has 11 references indexed in Scilit:
- Resistance to Protease InhibitorsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Nonnucleoside Reverse Transcriptase Inhibitor ResistanceJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Nucleoside Reverse Transcriptase Inhibitor ResistanceJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Resistance to Protease InhibitorsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Nonnucleoside Reverse Transcriptase Inhibitor ResistanceJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Nucleoside Reverse Transcriptase Inhibitor ResistanceJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance.Pharmacology & Therapeutics, 2000
- Epidemiology of Human Immunodeficiency Virus–Associated Opportunistic Infections in the United States in the Era of Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2000
- Antiretroviral drug resistance in HIV-1Current Infectious Disease Reports, 1999
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998